Med BioGene (MBGI) Files $24.25M IPO
Tweet Send to a Friend
Med BioGene, Inc. (NASDAQ: MBGI) filed a registration statement with the SEC for an initial public offering of its common stock. The proposed maximum aggregate offering price is $24.25 million. The company plans to list on the NASDAQ Capital Market under the stock symbol "MBGI."
The offering is being made through Rodman & Renshaw.
Med BioGene is a life science company focused on the development and commercialization of genomic-based clinical laboratory diagnostic tests for cancer.
The offering is being made through Rodman & Renshaw.
Med BioGene is a life science company focused on the development and commercialization of genomic-based clinical laboratory diagnostic tests for cancer.
You May Also Be Interested In
- Dan Loeb Builds Massive Stake in Sony (SNE), Wants Entertainment Arm Split
- MEMSIC Announces First-Quarter 2013 Results
- MEMSIC, Inc. (MEMS) Reports In-Line Q1 EPS
Create E-mail Alert Related Categories
IPOsRelated Entities
Rodman & Renshaw
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
